1 / 8

Endometrial Committee

Endometrial Committee. David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Dallas, Texas, U.S.A. PROPOSED GCIG STUDIES Other. GTN

howard
Download Presentation

Endometrial Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Dallas, Texas, U.S.A.

  2. PROPOSED GCIG STUDIESOther • GTN • GOG-0242: A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-Metastatic Gestational Trophoblastic Neoplasia • Carcinosarcoma: • GOG: UC-0701: A Randomized Phase III trial of Carboplatin Plus Paclitaxel vs. Ifosfamide Plus Paclitaxel in Chemotherapy Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus

  3. Resected Endometrial • GOG-0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer • RTOG • PORTEC 3: Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma • NCRI

  4. Resected Endometrial • EORTC?: The role of adjuvant chemotherapy in surgical stage I-II serous or clear cell endometrial carcinoma: a randomized phase III trial • NSGO: GCIG Phase III trial on adjuvant therapy in radically operated endometrial cancer patients with high risk for micro-metastatic disease: chemotherapy + radiotherapy (CT+RT) versus chemotherapy (CT • MITO: New adjuvant trial comparing sequential CT RT, as standard arm, versus CT only in FIGO Stage III

  5. Resected Endometrial • GOG: UC0704: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Cancer • RTOG

  6. Resected Endometrial • GOG-0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer • RTOG • PORTEC 3: Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma • NCRI

  7. Pelvic Recurrence • GOG-0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus • RTOG, NCRI

  8. Advanced/Recurrent • NCIC: Deforolimus vs. hormones: phase III RCT in women with metastatic/recurrent endometrial cancer • ACRIN, AGO-AUST, AGO-OVAR, ANZOG, EORTC, GEICO, JGOG, MITO, NCRI, NSGO

More Related